- Home
- ESGL vs PRLD Comparison
ESGL vs PRLD Comparison
Compare ESGL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- PRLD
- Stock Information
- Founded
- ESGL 1999
- PRLD 2016
- Country
- ESGL Singapore
- PRLD United States
- Employees
- ESGL N/A
- PRLD N/A
- Industry
- ESGL
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- ESGL
- PRLD Health Care
- Exchange
- ESGL Nasdaq
- PRLD Nasdaq
- Market Cap
- ESGL 64.6M
- PRLD 73.7M
- IPO Year
- ESGL N/A
- PRLD 2020
- Fundamental
- Price
- ESGL $2.00
- PRLD $0.77
- Analyst Decision
- ESGL
- PRLD Strong Buy
- Analyst Count
- ESGL 0
- PRLD 2
- Target Price
- ESGL N/A
- PRLD $4.50
- AVG Volume (30 Days)
- ESGL 55.9K
- PRLD 254.5K
- Earning Date
- ESGL 04-08-2025
- PRLD 03-10-2025
- Dividend Yield
- ESGL N/A
- PRLD N/A
- EPS Growth
- ESGL N/A
- PRLD N/A
- EPS
- ESGL N/A
- PRLD N/A
- Revenue
- ESGL $6,264,048.00
- PRLD $7,000,000.00
- Revenue This Year
- ESGL N/A
- PRLD N/A
- Revenue Next Year
- ESGL N/A
- PRLD N/A
- P/E Ratio
- ESGL N/A
- PRLD N/A
- Revenue Growth
- ESGL 12.87
- PRLD N/A
- 52 Week Low
- ESGL $0.42
- PRLD $0.63
- 52 Week High
- ESGL $3.00
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- ESGL 61.95
- PRLD 50.06
- Support Level
- ESGL $1.86
- PRLD $0.71
- Resistance Level
- ESGL $2.05
- PRLD $0.76
- Average True Range (ATR)
- ESGL 0.15
- PRLD 0.07
- MACD
- ESGL -0.01
- PRLD 0.02
- Stochastic Oscillator
- ESGL 81.94
- PRLD 58.46
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd Formerly Environmental Solutions Group Holdings Ltd is a waste management, treatment and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical and electroplating companies.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.